<DOC>
	<DOCNO>NCT00908869</DOCNO>
	<brief_summary>Purpose : This phase I trial estimate antiangiogenic antivascular effect 4 different level continuous low dos combination Vinorelbine , Cyclophosphamide Interferon alpha 2b ( `` metronomic chemotherapy `` ) adult advance neoplasm . This study non randomize , monocentric , pharmacodynamic part . Primary objective : Estimation toxicity combination continuous low dos Vinorelbine , Cyclophosphamide Interferon alpha 2b . Secondary objective : Estimation antiangiogenic and/or antivascular effect ( VEGF measurement ) radiography ( DEC-MRI ) , biology immunohistochemistry treatment .</brief_summary>
	<brief_title>Combination Continuous Low Doses Vinorelbine , Cyclophosphamide Interferon Alpha 2b ( `` Metronomic Chemotherapy `` ) Antiangiogenic Antivascular Effect . Trial With Pharmacodynamic Study Adult Advanced Neoplasm</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>patient age 18 old , metastatic advance solid tumor receive standard treatment , end chemotherapy radiotherapy treatment within 4 week ( 6 week mitocyne ) prior entry study . All patient include give write informed consent . patient stable disease , history presence another cancer , contraindication administer treatment , contraindication perform MRI , pregnancy breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>advanced neoplasm</keyword>
	<keyword>adult advance neoplasm</keyword>
</DOC>